Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources
New Report from Decision Resources Explores Near-Term Opportunities in the U.S. Generic Drug Market
BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that between 2013 and 2020, 40 blockbuster brands will lose patent exclusivity in the United States. According to the new Strategic Insights report entitled Indian Generics Manufacturers Penetrate U.S. Generics Market: Case Studies in Success and Failure and Near-Term Opportunities, the loss of brand sales to generics is forecasted to be more than $155 billion over this period. The largest single year loss of brand exclusivity will occur in 2015, and through 2020 the share of generics opportunities will increasingly shift from small-molecule drugs to branded biologics and recombinant proteins.
The report finds that while the U.S. generics industry is led by Teva, Mylan and Actavis, India-based firms continue to increase their presence in the U.S. generics market. India-based firms include Ranbaxy, Dr. Reddy's and Lupin, among others. However, despite their progress penetrating the U.S. generics market, Indian companies face a number of challenges, including the requirement for increased R&D spend and more advanced-manufacturing technologies to remain competitive as patent events increasingly shift from small-molecule generics to more-complex formulations.
"Teva is the leading global generics company and provides Indian companies with a template for successful growth," said Decision Resources Group Senior Vice President Kate Hohenberg. "The company's growth has been achieved largely through acquisitions to expand its global footprint and technological capabilities."
About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
©2012 PR Newswire. All Rights Reserved.